CHURCH & DWIGHT CO INC /DE/
Business
CHURCH & DWIGHT CO INC /DE/ develops, manufactures and markets a broad portfolio of consumer household and personal care products and specialty products serving animal and food production, industrial chemical and cleaning markets. Its main products include baking soda-based household cleaners and deodorizers, laundry detergents, stain removers, oral care, personal care and OTC items, dietary supplements, water flossers, and specialty animal nutrition and chemical products under well-known brands. The company operates three segments: Consumer Domestic, Consumer International, and Specialty Products Division. It distributes products through supermarkets, mass merchandisers, drugstores, wholesale clubs, specialty and discount retailers, e-commerce channels, subsidiaries and third‑party distributors across the U.S. and international markets.
Summary from filing dated 2025-02-13
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net Sales | 6,203 | 6,107 | 5,868 | 5,376 | 5,190 | |
| Cost of sales | 3,428 | 3,317 | 3,279 | 3,126 | 2,927 | |
| Gross Profit | 2,775 | 2,790 | 2,589 | 2,250 | 2,264 | |
| Marketing expenses | 709 | 698 | 641 | 535 | 578 | |
| Selling, general and administrative expenses | 988 | 928 | 890 | 706 | 607 | |
| VMS Trade name and other asset impairments | — | 357 | — | — | — | |
| Income from Operations | 1,078 | 807 | 1,057 | 598 | 1,079 | |
| Equity in earnings of affiliates | 8 | 9 | 9 | 12 | 9 | |
| Interest income | 24 | 26 | 13 | 4 | — | |
| Interest expense | −95 | −95 | −111 | −90 | −55 | |
| Other income (expense), net | −57 | 9 | −800,000 | −1 | −2 | |
| Income before Income Taxes | 957 | 756 | 967 | 523 | 1,032 | |
| Income taxes | 220 | 171 | 212 | 109 | 204 | |
| Net Income | 737 | 585 | 756 | 414 | 828 | |
| Weighted average shares outstanding - Basic | 243 | 244 | 245 | 243 | 245 | |
| Weighted average shares outstanding - Diluted | 244 | 247 | 248 | 246 | 250 | |
| Net income per share - Basic | 3.04 | 2.39 | 3.09 | 1.7 | 3.38 | |
| Net income per share - Diluted | 3.02 | 2.37 | 3.05 | 1.68 | 3.32 | |
| Cash dividends per share | 1.18 | 1.13 | 1.09 | 1.05 | 1.01 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 409 | 964 | 345 | 270 | 241 | |
| Accounts receivable, less allowances of $3.7 and $5.1 | 593 | 601 | 527 | 422 | 406 | |
| Inventories | 535 | 613 | 613 | 647 | 535 | |
| Other current assets | 60 | 62 | 45 | 57 | 52 | |
| Total Current Assets | 1,597 | 2,241 | 1,530 | 1,396 | 1,233 | |
| Property, Plant and Equipment, Net | 823 | 932 | 928 | 761 | 653 | |
| Equity Investment in Affiliates | 10 | 11 | 12 | 13 | 9 | |
| Trade Names and Other Intangibles, Net | 3,512 | 2,889 | 3,302 | 3,432 | 3,494 | |
| Goodwill | 2,628 | 2,433 | 2,432 | 2,427 | 2,275 | |
| Other Assets | 343 | 378 | 366 | 318 | 333 | |
| Total Assets | 8,912 | 8,883 | 8,569 | 8,346 | 7,997 | |
| Accounts payable | 732 | 705 | 631 | 667 | — | |
| Accrued expenses and other liabilities | 583 | 606 | 580 | 436 | — | |
| Business acquisition liabilities | 179 | 0 | — | — | — | |
| Income taxes payable | 3 | 5 | 7 | 7 | 3 | |
| Total Current Liabilities | 1,498 | 1,316 | 1,422 | 1,184 | 2,075 | |
| Long-term Debt | 2,205 | 2,205 | 2,202 | 2,600 | 2,202 | |
| Deferred Income Taxes | 887 | 669 | 743 | 757 | 745 | |
| Deferred and Other Long-term Liabilities | 321 | 333 | 314 | 273 | 298 | |
| Total Liabilities | 4,910 | 4,522 | 4,714 | 4,856 | 4,763 | |
| Commitments and Contingencies | — | — | — | — | — | |
| Preferred Stock, $1.00 par value, Authorized 2,500,000 shares; none issued | 0 | 0 | 0 | 0 | 0 | |
| Common Stock, $1.00 par value, Authorized 600,000,000 shares; 293,709,982 shares issued as of December 31, 2025 and 2024 | 294 | 294 | 294 | 294 | 293 | |
| Additional paid-in capital | 625 | 563 | 455 | 366 | 310 | |
| Retained earnings | 6,768 | 6,320 | 6,012 | 5,525 | 5,366 | |
| Accumulated other comprehensive loss | −20 | −31 | −27 | −29 | −68 | |
| Common stock in treasury, at cost: 57,156,105 shares as of December 31, 2025 and 47,830,141 shares as of December 31, 2024 | −3,665 | −2,785 | −2,878 | −2,665 | −2,668 | |
| Total Stockholders' Equity | 4,002 | 4,361 | 3,855 | 3,490 | 3,233 | |
| Total Liabilities and Stockholders Equity | 8,912 | 8,883 | 8,569 | 8,346 | 7,997 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 90 | 83 | 73 | 67 | 68 | |
| Amortization expense | 158 | 156 | 152 | 152 | 151 | |
| Change in fair value of business acquisition liabilities | 19 | 0 | 0 | — | — | |
| Deferred income taxes | 36 | −82 | −14 | −118 | 20 | |
| Business exit related impairments | 46 | 0 | 0 | — | — | |
| Loss on sale of vitamin business | 59 | 0 | 0 | — | — | |
| Equity in net earnings of affiliates | −8 | −9 | −9 | −12 | −9 | |
| Distributions from unconsolidated affiliates | 9 | 9 | 10 | 9 | 9 | |
| Non-cash compensation expense | 58 | 59 | 64 | 32 | 24 | |
| Asset impairment charge and other asset write-offs | 10 | 12 | 9 | 2 | 15 | |
| Other | −7 | −6 | −400,000 | −3 | 4 | |
| Subtotal | 1,206 | 1,164 | 1,040 | — | — | |
| Accounts receivable | 39 | −82 | −97 | −5 | 2 | |
| Inventories | 56 | 2 | 39 | −93 | −29 | |
| Other current assets | 1 | −500,000 | 10 | 3 | −6 | |
| Accounts payable | 2 | 99 | −58 | 7 | — | |
| Accrued expenses | −61 | −1 | 113 | 33 | — | |
| Income taxes payable | −5 | −7 | −2 | 14 | −16 | |
| Other operating assets and liabilities, net | −23 | −19 | −14 | −28 | −16 | |
| Change in Working Capital | 10 | −8 | −9 | — | — | |
| Net Cash Provided By Operating Activities | 1,215 | 1,156 | 1,031 | 885 | 994 | |
| Additions to property, plant and equipment | −122 | −180 | −224 | −179 | −119 | |
| Acquisitions | −656 | −20 | 0 | −547 | −556 | |
| Proceeds from Sale of Passport | 0 | 7 | 0 | 0 | 0 | |
| Proceeds from Sale of Vitamin Business | 160 | 0 | 0 | — | — | |
| Other | 1 | 10 | −11 | −3 | −7 | |
| Net Cash Used In Investing Activities | −617 | −183 | −234 | −729 | −682 | |
| Repayments of long-term debt | 0 | −205 | −200 | −700 | −300 | |
| Short-term debt (repayments), net of borrowings | 0 | −4 | −71 | −179 | −99 | |
| Proceeds from stock options exercised | 36 | 143 | 112 | 26 | 99 | |
| Payment of cash dividends | −287 | −277 | −267 | −255 | −248 | |
| Purchase of treasury stock | −900 | 0 | −300 | 0 | −500 | |
| Payment of business acquisition liability | −6 | 0 | 0 | — | — | |
| Other | −5 | −1 | −100,000 | — | — | |
| Net Cash Used In Financing Activities | −1,162 | −343 | −726 | −121 | −252 | |
| Effect of exchange rate changes on cash and cash equivalents | 9 | −10 | 4 | −6 | −2 | |
| Net Change In Cash and Cash Equivalents | −555 | 620 | 74 | 30 | 58 | |
| Interest (net of amounts capitalized) | 95 | 94 | 112 | 86 | 52 | |
| Income taxes | 188 | 260 | 228 | 213 | 203 | |
| Property, plant and equipment expenditures included in Accounts Payable | 17 | 11 | 31 | 14 | 11 |